The FAVOUR study's interim analysis results on Alflutinib Mesylate for treating EGFR exon 20-insertion mutated NSCLC were orally presented at the 2023 WCLC. The drug is developed by Shanghai Allist Pharmaceuticals and ArriVent Biopharma.
Research and development (R&D) efforts in biopharmaceuticals are high, cycles are long, and risks are significant. Companies in this industry heavily rely on core technologies, specialized talents, and intellectual property protection. Drug patents' freedom to operate (FTO) is crucial for determining whether drug candidates can be further commercialized.
On Sept 11, 2023, Chia Tai Tianqing Pharmaceutical launched a global phase III trial, evaluating Lanifibranor's efficacy and safety in adult NASH patients with stage 2/3 hepatic fibrosis, excluding cirrhosis.
On September 11, 2023, Abbisko Therapeutics announced that its innovative CSF-1R inhibitor pimicotinib (ABSK021) was approved by the European Medicines Agency.
The progress of R&D efforts in a life-science area of study can greatly affect the likelihood of breakthroughs and advancements. So, how do we analyze the global research and development progress of the sequence we are studying? I recommend that you use the Patsnap Bio Sequence Database to query data and information.